Moderna Inc

21. Aug. 2026, 23:36 UTC

Moderna Inc. shares are higher in after-market trading following a successful melanoma trial, reflecting strong investor interest and elevated trading volume.

20. Aug. 2026, 23:01 UTC

Moderna Inc. shares are lower in after-market trading amid skepticism about its mRNA cancer vaccine and broader declines in U.S. stocks following Walmart's poor performance.

19. Aug. 2026, 23:51 UTC

Moderna shares lower in after-market trading despite positive Phase 3 results for its mRNA cancer vaccine, which boosted market cap by over $50 billion.

18. Aug. 2026, 23:51 UTC

MAHA shares are lower in after-market trading amid growing disappointment over the FDA's approval of Moderna's mRNA flu shot and recent departures from the agency.

17. Aug. 2026, 20:06 UTC

Concerns about the FDA's approval of Moderna's flu vaccine persist. Shares are higher today, remaining above the 20-day moving average.

14. Aug. 2026, 23:51 UTC

Moderna shares are lower in after-market hours amid concerns over the FDA's approval of its mRNA flu vaccine and modest trial data effectiveness.

13. Aug. 2026, 23:21 UTC

Moderna's first mRNA flu shot receives FDA approval, despite concerns over a high adverse reaction rate. Shares are higher in after-market trading.

12. Aug. 2026, 23:51 UTC

Moderna Inc shares are lower in after-market hours with no specific news identified. Recent easing inflation has influenced broader market sentiment.

10. Aug. 2026, 19:36 UTC

The FDA has approved Moderna's mRNA flu vaccine for adults 50 and older. Shares are advancing modestly amid concerns over safety and efficacy.

7. Aug. 2026, 19:52 UTC

The FDA approved Moderna's mRNA flu vaccine, mFlusiva, for adults 50 and older. Shares are higher during Friday's trading session.

6. Aug. 2026, 23:06 UTC

Moderna's mRNA flu vaccine, "mFlusiva," receives FDA approval for adults aged 50 to 64, boosting shares higher in after-market trading.

5. Aug. 2026, 19:46 UTC

Moderna Inc. shares are lower as disappointing ADP employment data weighs on market sentiment. The FDA has set a decision date for its mFlusiva vaccine.

4. Aug. 2026, 20:07 UTC

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

3. Aug. 2026, 20:03 UTC

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

31. Juli 2026, 23:26 UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

30. Juli 2026, 23:51 UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

29. Juli 2026, 23:51 UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

28. Juli 2026, 18:36 UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

27. Juli 2026, 19:07 UTC

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

24. Juli 2026, 19:03 UTC

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

23. Juli 2026, 19:56 UTC

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

21. Juli 2026, 20:07 UTC

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

20. Juli 2026, 23:46 UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.